The study has been performed by Accelera S.r.l. (Nerviano, Italy). All the animal procedures were performed according to the current Italian legislation (Legislative Decree March 4th, 2014 n. 26) enforcing the 2010/63/EU Directive on the protection of animals used for biomedical research. AbDec-L1 has been administered by single intravenous injection to adult female Sprague Dawley rats (n=3) at the dose of 20 mg/kg. The serum levels of the molecule were evaluated at pre-dose and after 5 min, 30 min, 1, 4, 8, 24, 48, 72, 168 and 240 h post-dosing. The compound in serum was analyzed by an ELISA assay based on solid phase extraction with DO24 anti-MET antibody (2.5 μg/mL). Calibration curve was obtained loading different concentrations of the purified AbDec-L1 (range 0.0425–47.6 μg/mL) diluted in rat serum. AbDec-L1 was revealed using horseradish peroxidase (HRP)-conjugated anti-human k light chain antibodies. The pharmacokinetic profile of the compound was analyzed by standard non compartmental analysis using Phoenix-WinNonlin package (v. 8.1, Certara Company, USA). Samples at time 0, 48, 72, 168, and 240 h post-dosing were below the lower limit of quantification.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.